

TRANSFORMING HEALTHCARE THROUGH PERSONALIZED MEDICINE

*Bridge Big Data in Molecular Biology and Clinical Application
Practice Individual Curated Precision Medicine*




VISHU Biomedical is a Singapore based healthcare technology company dedicated to establish personalized medicine for prognosis, diagnosis and treatment. It delivers genomic sequence analysis to research institutes, health screening clinics, hospitals and pharmaceutical industry.

Its core product, iCMDB, advances customized analysis of diseases on molecular level.

What is iCMDB

iCMDB (individual Customized Medicine Database) is an integrated sequence analysis platform. It is tailored to clinicians in conducting personalized treatment based on patients' genetic profiles. It comprises four manually curated datasets – Drug, Disease, Nutrition and Patient Review. The content is constantly reviewed and validated by experts in life sciences and medical consultants.



- o Analyze consolidated data from Sanger and Next-Gen sequencing, qPCR, FISH
- o Compatible with all sequencers on market
- o Differential analysis parameters for various sample types
- o Unprecedented computing power reduces analysis lead time
- o Clinical annotation from high quality of evidence
- o ISO13485:2003 certified

Automated iCMDB Report

iCMDB automatically generates two reports – Quality Control Report and Pathology Report, for pathologists and clinicians to verify analysis outcome and adopt optimal treatment plan.

Quality Control Report

Quality Control Report

Patient Information

Name of Patient: E.P.H.02192402 Patient ID: 000102
 Date of Birth: 1970-01-01
 Sex: Male
 Date of Test: 2019-08-20
 Test Name: iCMDB
 Referring Physician: Dr. [Name]
 Referring Institution: [Institution]
 Disease Description: Non-Small Cell Lung Cancer
 Family History: N/A

Test Information

Name: [Name]
 Ref: [Ref]
 Number of Copies: [Number]
 Number of Reads: [Number]
 LAF Clones: [Number]

Database and Software Version

Database: [Version]
 Software: [Version]

Sample Summary

No.	Sample ID	Sample Source	Sex	Description
1	000102	Whole Blood	M	1 year before first treatment
2	000102	Whole Blood	M	Before first treatment
3	000102	Whole Blood	M	After first treatment
4	000102	Whole Blood	M	After first treatment
5	000102	FFPE	M	After first treatment
6	000102	FFPE Tissue	M	After first treatment

Page 1 of 4

Mutation QC


1) Single Mutation

No.	Gene	RefSeq	Alt Mutation	DB Mutation	Chr	Pos	Alt Position	Sample ID	COG
1	EGFR	c.1173T>C	G62	G52	7	316	4132	000102	Gain
2	EGFR	c.2156A>G	L858R	L858R	7	316	4132	000102	Gain
3	EGFR	c.2156A>G	L858R	L858R	7	316	4132	000102	Gain
4	EGFR	c.2156A>G	L858R	L858R	7	316	4132	000102	Gain
5	EGFR	c.2156A>G	L858R	L858R	7	316	4132	000102	Gain

2) Somatic/Hereditary Mutation

No.	Gene	RefSeq	Alt Mutation	DB Mutation	Chr	Pos	Alt Position	Sample ID	COG
1	EGFR	c.1173T>C	G62	G52	7	316	4132	000102	Gain
2	EGFR	c.2156A>G	L858R	L858R	7	316	4132	000102	Gain
3	EGFR	c.2156A>G	L858R	L858R	7	316	4132	000102	Gain
4	EGFR	c.2156A>G	L858R	L858R	7	316	4132	000102	Gain
5	EGFR	c.2156A>G	L858R	L858R	7	316	4132	000102	Gain

Page 2 of 4



- o Summary of Database and Software Version
- o Cross-QC by Technician and Lab Director

- o Somatic and Hereditary Mutation Differentiation through Tests from Different Samples

- o Intuitive Base Quality, Read Quality, Read Length and Target Coverage Plot

Pathology Report

Pathology Report

Patient Information

Name of Patient: E.P.H.02192402 Patient ID: 000102
 Date of Birth: 1970-01-01
 Sex: Male
 Date of Test: 2019-08-20
 Test Name: iCMDB
 Referring Physician: Dr. [Name]
 Referring Institution: [Institution]
 Disease Description: Non-Small Cell Lung Cancer
 Family History: N/A

Test Information

Name: [Name]
 Ref: [Ref]
 Number of Copies: [Number]
 Number of Reads: [Number]
 LAF Clones: [Number]

Analysis Reference Used

Reference: [Reference]
 COG: [COG]

Sample Summary

No.	Sample ID	Sample Source	Sex	Description
1	000102	Whole Blood	M	1 year before first treatment
2	000102	Whole Blood	M	Before first treatment
3	000102	Whole Blood	M	After first treatment
4	000102	FFPE	M	After first treatment
5	000102	FFPE Tissue	M	After first treatment

Page 1 of 4

Summary Results

No.	Gene	Alt Mutation	DB Mutation	Chr	Pos	Alt Position	Sample ID	COG
1	EGFR	c.1173T>C	G62	7	316	4132	000102	Gain
2	EGFR	c.2156A>G	L858R	7	316	4132	000102	Gain
3	EGFR	c.2156A>G	L858R	7	316	4132	000102	Gain
4	EGFR	c.2156A>G	L858R	7	316	4132	000102	Gain
5	EGFR	c.2156A>G	L858R	7	316	4132	000102	Gain

EBM Treatment Plan

Plan: [Plan]

Pathologist Information

Pathologist: [Name]
 Institution: [Institution]

Page 2 of 4

Clinical Trial Records

1) Clinical Trial Records

Name of Patient: E.P.H.02192402 Patient ID: 000102
 Date of Birth: 1970-01-01
 Sex: Male
 Date of Test: 2019-08-20
 Test Name: iCMDB
 Referring Physician: Dr. [Name]
 Referring Institution: [Institution]
 Disease Description: Non-Small Cell Lung Cancer
 Family History: N/A

Pathology Comment

[Detailed text comment]

Page 3 of 4

Pathology Comment

[Detailed text comment]

Pathologist Decision on Record

APPROVED REJECTED

Page 4 of 4

- o Patient Information
- o Biomarker List
- o Phase-wise Sample Collection

- o Mutation COSMIC Information
- o Comprehensive Evidence-based Medicine Plan

- o Latest Clinical Trial Records
- o Trustworthy Source of Medicine Information

- o Diagram of Mutation associated Pathway
- o Pathologist Decision on Record

VISHUO BIOMEDICAL



SINGAPORE

#03-35A Teletech Park
20 Science Park Road
Singapore 117674
info@vishuo.com
Tel: 65 6774 1566

CHINA

Floor 8 Wanrun Building
1 Haiying Road
Fengtai District
Beijing
info_cn@vishuo.com
Tel: 400 0010 937

AUSTRALIA (Distributor)

Custom Science Pty Ltd
info@customscience.com.au


customscience